Terminated PHASE1 INTERVENTIONAL 4-arm NCT05389462

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Sponsor: ADC Therapeutics S.A.

Conditions Advanced Solid Tumors

Interventions ADCT-601 Gemcitabine

Updated 15 times since 2022 Last updated: May 19, 2025 Started: Jul 13, 2022 Primary completion: Apr 17, 2025 Completion: Apr 17, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decided to halt further development of ADCT-601

Other terminated trials from ADC Therapeutics S.A.

More terminations from ADC Therapeutics S.A.

Other Advanced Solid Tumors trials with similar outcome

Browse all Advanced Solid Tumors trials

A PHASE1 clinical study on Advanced Solid Tumors, this trial is terminated or withdrawn. The trial is conducted by ADC Therapeutics S.A. and has accumulated 15 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Jun 2025 — Sep 2025 [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated
Jan 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

▶ Show 10 earlier versions

May 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Jan 2024 — May 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Jun 2023 — Nov 2023 [monthly]

Recruiting PHASE1
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Feb 2023 — May 2023 [monthly]

Recruiting PHASE1
Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE1
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE1
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jun 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ADC Therapeutics S.A.

Data source: ADC Therapeutics S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bordeaux, France , Iowa City, United States , London, United Kingdom , Lyon, France , Madrid, Spain , Manchester, United Kingdom , Nashville, United States , Nice, France , Oklahoma City, United States and 3 more locations